New Treatment for Cutaneous T-Cell Lymphoma Fast-Tracked
According to biopharmaceutical company Soligenix, the US Food and Drug Administration has fast-tracked the company's experimental treatment SGX301 for the front-line treatment of patients with cutaneous t-cell lymphoma (CTCL).
SGX301, synthetic hypericin, is listed as a first-in-class photodynamic therapy. It uses safe visible light for activation. Synthetic hypericin is a photosensitizer applied topically to skin lesions and then activated by using fluorescent light. Pre-clinical and clinical studies have shown that hypericin combined with photoactivation can have significant antiproliferative effects on activated normal lymphoid cells and can contribute to inhibiting the growth of malignant T-cells in patients diagnosed with CTCL.
A phase II study of SGX301 in CTCL patients showed a statistically significant improvement in patients using the topical SGX301 (58.3 percent) compared to patients given a placebo (8.3 percent).
Read more about SGX301 at Soligenix.com.
Adapted from press release.
More Articles
More Articles
Amazon.com is pleased to have the Lymphoma Information Network in the family of Amazon.com associates. We've agreed to ship items...
The question ought to be what are myelodysplastic syndromes (MDS), since this is a group of similar blood and bone marrow diseases that...
Merkel Cell Carcinoma (MCC) is a very rare and aggressive skin cancer that usually develops when a person is in his or her 70s. It is...
At some point, the Seattle biotech company Cell Therapeutics Inc (CTI) should earn an entry in the Guinness Book of World Records for utter and...
Site Beginnings
This site was started as Lymphoma Resource Page(s) in 1994. The site was designed to collect lymphoma...
Three papers appearing in the journal Blood and pointing towards a regulator-suppressor pill could offer hope to blood cancer...
The US Food and Drug Administration (FDA) has granted a third so-called Breakthrough Therapy Designation for the investigational oral...
The US Food and Drug Administration today has approved an expanded use of Imbruvica (ibrutinib) in patients with...
The U.S. Food and Drug Administration has announced that it has granted "Breakthrough Therapy Designation" for the investigational agent...
According to a new study published in the Proceedings of the National Academy of Sciences, a team from the University of California, San...
Pharmacyclics has announced that the company has submitted a New Drug Application (NDA) to the US Food and Drug Administration (FDA) for...
New research suggests that frontline radioimmunotherapy...
Gilead Sciences has announced results of the company's Phase II study of its investigational compound idelalisib, an oral inhibitor of...
